Product Description
Injection use LX22001 is a Potassium-Competitive Acid Blockers (P-CAB), which inhibits acid secretion by competitively binding with the potassium binding site of H+/K+-ATPase (proton pump) in wall cells. Unlike proton pump inhibitors (PPIs), P-CAB can directly inhibit H+/K+-ATPase without activation in highly acidic environments. And regardless of whether H+/K+-ATPase is activated or not, P-CAB can bind. Injection use LX22001 is a new improved drug based on the known active ingredient tegoprazan, and is clinically intended for: (1) alternative therapy for reflux esophagitis and duodenal ulcers when oral treatment is not suitable, and (2) bleeding from gastrointestinal ulcers. (Sourced from: https://news.futunn.com/en/post/44384931/luoxin-pharmaceuticals-group-stock-002793-sz-injection-lx22001-has-been?level=1&data_ticket=1724682875348575)
Mechanisms of Action: P-CA Blocker
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shandong Luoxin Pharmaceutical Group Co., Ltd./Luoxin Pharmaceutical (Shanghai) Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|